Residential and Outpatient Schizophrenia Patients' Sleep Health Differs.

Published Date: 27 Apr 2023

Residential and Outpatient Schizophrenia Patients' Sleep Health Varies.

Read Full News

Latest News

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Todays Updates

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome

Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome

Todays Updates

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome

Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome

Latest News

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

News All Time

Soft Drinks Linked to Depression Through Gut Microbiota Alterations Chelsie Derman

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Early Heart Rate Slowing Predicts Magnetic Brain Stimulation Response in MDD Chelsie Derman

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial Chelsie Derman

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder Chelsie Derman

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Esmethadone Shows Promise as Adjunctive Treatment for Antidepressant Tolerance Chelsie Derman

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

Magnetic Seizure Therapy Rivals ECT, Protects Cognition in Adolescent MDD Chelsie Derman

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

Antidepressants Differ Significantly in Cardiometabolic Side Effects Chelsie Derman

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Repetitive TMS Boosts Quality of Life in Younger, Older Adults with Depression Chelsie Derman

Study finds repetitive transcranial magnetic stimulation brings clinically meaningful improvements in quality of life for adults with MDD through 12 weeks.

Comorbid Anxiety Lowers Accelerated Theta Burst Response in Depression Chelsie Derman

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Rethinking Addiction Recovery: From Symptoms to Systems

Rethinking Addiction Recovery: From Symptoms to Systems

Non-Invasive Vagus Nerve Stimulation Boosts Food Liking in Depression Chelsie Derman

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

Women Face Higher Risk of Advanced Fibrosis Due to Binge Drinking Than Men

Women Face Higher Risk of Advanced Fibrosis Due to Binge Drinking Than Men

Stigma Around Alcohol-Related Liver Disease Poses Major Barrier to Care

Stigma Around Alcohol-Related Liver Disease Poses Major Barrier to Care

6 Psychiatry Headlines You Missed in October 2025

6 Psychiatry Headlines You Missed in October 2025

Tracing schizophrenia's origins: Study maps chromatin accessibility in postmortem brain tissue

Schizophrenia is a severe neuropsychiatric disorder characterized by hallucinations, false beliefs about oneself or the world (i.e., delusions), and other disruptions in thought, emotion and perception. Recent genetic studies ...

Not all PTSD therapies keep veterans in treatment, study warns

About a quarter of U.S. service members and veterans who start psychotherapy for post-traumatic stress disorder quit before they finish treatment. But not all therapies are equal in their appeal, with some effective approaches ...

Recommended News For You

Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

Chemoradiation Plus Immunotherapy Fails to Improve Survival in Limited-Stage SCLC

Study recommends new grading system for invasive squamous cell carcinoma of the lung

Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions

Recommended Articles For You

Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations 

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment 

The Significance of APTT Blood Test Results for Detecting Coagulation Disorders 

Introduction To Immune Thrombocytopenic Purpura 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A study outlines the need for policies that enhance cancer patients' autonomy and information.

2.

Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk

3.

Radiation therapy for patients with breast cancer

4.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

5.

No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says

1.

The Predictive Power of Targeted Radionuclide Therapy in Advanced Breast Cancer

2.

Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025

3.

Innovative Strategies in Prostate Cancer Management: From Surveillance to Systemic Therapies

4.

Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment

5.

Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part I

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

4.

Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.

5.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot